COVID-19 in Australia: our national response to the first cases of SARS-CoV-2 infection during the early biocontainment phase.
COVID-19
SARS-CoV-2
clinical characteristics
models of care
pandemic
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
07
2020
revised:
27
08
2020
accepted:
27
08
2020
pubmed:
17
11
2020
medline:
25
2
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
On 31 December 2019, the World Health Organization recognised clusters of pneumonia-like cases due to a novel coronavirus disease (COVID-19). COVID-19 became a pandemic 71 days later. To report the clinical and epidemiological features, laboratory data and outcomes of the first group of 11 returned travellers with COVID-19 in Australia. This is a retrospective, multi-centre case series. All patients with confirmed COVID-19 infection were admitted to tertiary referral hospitals in New South Wales, Queensland, Victoria and South Australia. The median age of the patient cohort was 42 years (interquartile range (IQR), 24-53 years) with six men and five women. Eight (72.7%) patients had returned from Wuhan, one from Shenzhen, one from Japan and one from Europe. Possible human-to-human transmission from close family contacts in gatherings overseas occurred in two cases. Symptoms on admission were fever, cough and sore throat (n = 9, 81.8%). Co-morbidities included hypertension (n = 3, 27.3%) and hypercholesterolaemia (n = 2, 18.2%). No patients developed severe acute respiratory distress nor required intensive care unit admission or mechanical ventilation. After a median hospital stay of 14.5 days (IQR, 6.75-21), all patients were discharged. This is a historical record of the first COVID-19 cases in Australia during the early biocontainment phase of the national response. These findings were invaluable for establishing early inpatient and outpatient COVID-19 models of care and informing the management of COVID-19 over time as the outbreak evolved. Future research should extend this Australian case series to examine global epidemiological variation of this novel infection.
Sections du résumé
BACKGROUND
On 31 December 2019, the World Health Organization recognised clusters of pneumonia-like cases due to a novel coronavirus disease (COVID-19). COVID-19 became a pandemic 71 days later.
AIM
To report the clinical and epidemiological features, laboratory data and outcomes of the first group of 11 returned travellers with COVID-19 in Australia.
METHODS
This is a retrospective, multi-centre case series. All patients with confirmed COVID-19 infection were admitted to tertiary referral hospitals in New South Wales, Queensland, Victoria and South Australia.
RESULTS
The median age of the patient cohort was 42 years (interquartile range (IQR), 24-53 years) with six men and five women. Eight (72.7%) patients had returned from Wuhan, one from Shenzhen, one from Japan and one from Europe. Possible human-to-human transmission from close family contacts in gatherings overseas occurred in two cases. Symptoms on admission were fever, cough and sore throat (n = 9, 81.8%). Co-morbidities included hypertension (n = 3, 27.3%) and hypercholesterolaemia (n = 2, 18.2%). No patients developed severe acute respiratory distress nor required intensive care unit admission or mechanical ventilation. After a median hospital stay of 14.5 days (IQR, 6.75-21), all patients were discharged.
CONCLUSIONS
This is a historical record of the first COVID-19 cases in Australia during the early biocontainment phase of the national response. These findings were invaluable for establishing early inpatient and outpatient COVID-19 models of care and informing the management of COVID-19 over time as the outbreak evolved. Future research should extend this Australian case series to examine global epidemiological variation of this novel infection.
Identifiants
pubmed: 33196128
doi: 10.1111/imj.15105
pmc: PMC7753759
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-51Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Virus Evol. 2020 Apr 10;6(1):veaa027
pubmed: 32296544
Osong Public Health Res Perspect. 2020 Feb;11(1):8-14
pubmed: 32149037
Commun Dis Intell (2018). 2020 Aug 07;44:
pubmed: 32829699
J Med Virol. 2020 Jun;92(6):680-682
pubmed: 32124995
Int J Infect Dis. 2020 Sep;98:372-380
pubmed: 32623083
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
Sci Rep. 2017 Sep 7;7(1):10917
pubmed: 28883450
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Influenza Other Respir Viruses. 2020 Jul;14(4):374-379
pubmed: 32223012
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Clin Microbiol Infect. 2020 Jul;26(7):948.e1-948.e3
pubmed: 32360780
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Korean Med Sci. 2020 Apr 06;35(13):e142
pubmed: 32242348
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):312-313
pubmed: 32191689
Emerg Microbes Infect. 2020 Dec;9(1):469-473
pubmed: 32102625
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Clin Nurs. 2020 Nov;29(21-22):3901-3904
pubmed: 32498115
J Virol. 2011 Dec;85(23):12815-20
pubmed: 21957308
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Med. 2020 Sep;26(9):1398-1404
pubmed: 32647358
Elife. 2020 May 11;9:
pubmed: 32392129
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Commun Dis Intell (2018). 2020 Mar 19;44:
pubmed: 32192424
N Engl J Med. 2020 May 21;382(21):e74
pubmed: 32383832
Disaster Med Public Health Prep. 2020 Aug;14(4):506-513
pubmed: 32207674
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Virol J. 2014 Jun 18;11:113
pubmed: 24942807
Commun Dis Intell (2018). 2020 Jul 14;44:
pubmed: 32664828
Genome Announc. 2017 May 11;5(19):
pubmed: 28495775
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553062
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930